<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03023826</url>
  </required_header>
  <id_info>
    <org_study_id>15567</org_study_id>
    <secondary_id>I7X-MC-LLCE</secondary_id>
    <nct_id>NCT03023826</nct_id>
  </id_info>
  <brief_title>A Study of LY3202626 in Healthy Participants</brief_title>
  <official_title>Relative Bioavailability and Food Effect Study in Healthy Subjects Administered Two Different Formulations of LY3202626</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purposes of this study are to determine:&#xD;
&#xD;
        -  If there are any differences in the way LY3202626 is handled by the body when taken in&#xD;
           two different forms&#xD;
&#xD;
        -  Whether a high fat meal affects the way the body handles LY3202626&#xD;
&#xD;
        -  How well tolerated LY3202626 is&#xD;
&#xD;
      There are three (3) study periods for all participants. Participants will be admitted to the&#xD;
      clinical research unit (CRU) each period and will be discharged from the CRU following the&#xD;
      completion of 2 overnight stays and up to 36 hours after dosing with LY3202626.&#xD;
&#xD;
      The study will last about 50 days, not including screening.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 15, 2017</start_date>
  <completion_date type="Actual">April 4, 2017</completion_date>
  <primary_completion_date type="Actual">April 4, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY3202626</measure>
    <time_frame>Predose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, 168 Hours Postdose</time_frame>
    <description>Pharmacokinetics (PK) is the maximum observed drug concentration (Cmax) of LY3202626</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of LY3202626</measure>
    <time_frame>Predose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, 168 Hours Postdose</time_frame>
    <description>PK is the area under the concentration versus time curve from time zero to infinity (AUC[0-∞]) of LY3202626</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: AUC From Time Zero to Time t, Where t is the Last Time Point With a Measurable Concentration (AUC[0-tlast]) of LY3202626</measure>
    <time_frame>Predose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, 168 Hours Postdose</time_frame>
    <description>PK is the AUC from time zero to time t, where t is the last time point with a measurable concentration (AUC[0-tlast]) of LY3202626</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>LY3202626 (R-Fasting)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of LY3202626 (R) capsule under fasting conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3202626 (T1-Fasting)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of LY3202626 (T1) tablet under fasting conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3202626 (T1-Fed)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of LY3202626 (T1) following a high fat breakfast.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3202626 (R-Fasting)</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>LY3202626 (R-Fasting)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3202626 (T1-Fasting)</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>LY3202626 (T1-Fasting)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3202626 (T1-Fed)</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>LY3202626 (T1-Fed)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Are overtly healthy males or females, as determined by medical history and physical&#xD;
             examination&#xD;
&#xD;
          -  Female participants must be of non-childbearing potential confirmed by medical history&#xD;
             or menopause&#xD;
&#xD;
          -  Have a body mass index (BMI) of 18.5 to 32.0 kilograms per meter squared (kg/m²)&#xD;
             inclusive, at screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Are investigative site personnel directly affiliated with this study and their&#xD;
             immediate families&#xD;
&#xD;
          -  Are currently enrolled in a clinical trial involving an investigational product or any&#xD;
             other type of medical research judged not to be scientifically or medically compatible&#xD;
             with this study&#xD;
&#xD;
          -  Have participated, within the last 30 days, in a clinical trial involving an&#xD;
             investigational product. If the previous investigational product has a long half-life,&#xD;
             3 months or 5 half-lives (whichever is longer) should have passed&#xD;
&#xD;
          -  Have previously completed or withdrawn from this study or any other study&#xD;
             investigating LY3202626, and have previously received the investigational product&#xD;
&#xD;
          -  Have a history of or current cardiovascular, respiratory, hepatic, renal,&#xD;
             gastrointestinal, endocrine, hematological, or neurological disorders capable of&#xD;
             significantly altering the absorption, metabolism, or elimination of drugs; of&#xD;
             constituting a risk when taking the investigational product; or of interfering with&#xD;
             the interpretation of data&#xD;
&#xD;
          -  Have a history of head trauma with loss of consciousness within the last 5 years&#xD;
&#xD;
          -  Have known or ongoing psychiatric disorders&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.</name>
      <address>
        <city>Singapore</city>
        <zip>117597</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 16, 2017</study_first_submitted>
  <study_first_submitted_qc>January 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2017</study_first_posted>
  <results_first_submitted>March 22, 2021</results_first_submitted>
  <results_first_submitted_qc>March 22, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 19, 2021</results_first_posted>
  <last_update_submitted>March 22, 2021</last_update_submitted>
  <last_update_submitted_qc>March 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 10, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/26/NCT03023826/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 17, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/26/NCT03023826/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participants were randomized to 1 of 6 sequences in 3 periods.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sequence (ACB)</title>
          <description>A: Reference (R): Single oral 12 milligram (mg) dose of LY3202626 capsule (R) under fasting conditions.&#xD;
B: Test (T1-12): Single oral 12 mg dose of LY3202626 tablet (T1) under fasting conditions.&#xD;
C: Test (T1-12): Single oral 12 mg dose of LY3202626 tablet (T1) following a high fat breakfast.</description>
        </group>
        <group group_id="P2">
          <title>Sequence (CAB)</title>
          <description>A: Reference (R): Single oral 12 milligram (mg) dose of LY3202626 capsule (R) under fasting conditions.&#xD;
B: Test (T1-12): Single oral 12 mg dose of LY3202626 tablet (T1) under fasting conditions.&#xD;
C: Test (T1-12): Single oral 12 mg dose of LY3202626 tablet (T1) following a high fat breakfast.</description>
        </group>
        <group group_id="P3">
          <title>Sequence (BAC)</title>
          <description>A: Reference (R): Single oral 12 milligram (mg) dose of LY3202626 capsule (R) under fasting conditions.&#xD;
B: Test (T1-12): Single oral 12 mg dose of LY3202626 tablet (T1) under fasting conditions.&#xD;
C: Test (T1-12): Single oral 12 mg dose of LY3202626 tablet (T1) following a high fat breakfast.</description>
        </group>
        <group group_id="P4">
          <title>Sequence (ABC)</title>
          <description>A: Reference (R): Single oral 12 milligram (mg) dose of LY3202626 capsule (R) under fasting conditions.&#xD;
B: Test (T1-12): Single oral 12 mg dose of LY3202626 tablet (T1) under fasting conditions.&#xD;
C: Test (T1-12): Single oral 12 mg dose of LY3202626 tablet (T1) following a high fat breakfast.</description>
        </group>
        <group group_id="P5">
          <title>Sequence (BCA)</title>
          <description>A: Reference (R): Single oral 12 milligram (mg) dose of LY3202626 capsule (R) under fasting conditions.&#xD;
B: Test (T1-12): Single oral 12 mg dose of LY3202626 tablet (T1) under fasting conditions.&#xD;
C: Test (T1-12): Single oral 12 mg dose of LY3202626 tablet (T1) following a high fat breakfast.</description>
        </group>
        <group group_id="P6">
          <title>Sequence (CBA)</title>
          <description>A: Reference (R): Single oral 12 milligram (mg) dose of LY3202626 capsule (R) under fasting conditions.&#xD;
B: Test (T1-12): Single oral 12 mg dose of LY3202626 tablet (T1) under fasting conditions.&#xD;
C: Test (T1-12): Single oral 12 mg dose of LY3202626 tablet (T1) following a high fat breakfast..</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least One Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants who received at least one dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>Single oral 12 mg dose of LY3202626 capsule (R) under fasting conditions, LY3202626 tablet (T1) under fasting conditions and LY3202626 tablet (T1) following a high-fat meal.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.2" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Singapore</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY3202626</title>
        <description>Pharmacokinetics (PK) is the maximum observed drug concentration (Cmax) of LY3202626</description>
        <time_frame>Predose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, 168 Hours Postdose</time_frame>
        <population>All randomized participants who received at least one dose and who had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>12 mg LY3202626 (R-Fasting)</title>
            <description>Single oral 12 mg dose of LY3202626 capsule (R) under fasting conditions.</description>
          </group>
          <group group_id="O2">
            <title>12 mg LY3202626 (T1-Fasting)</title>
            <description>Single oral 12 mg dose of LY3202626 tablet (T1) under fasting conditions.</description>
          </group>
          <group group_id="O3">
            <title>12 mg LY3202626 (T1-Fed)</title>
            <description>Single oral 12 mg dose of LY3202626 tablet (T1) following a high fat breakfast.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY3202626</title>
          <description>Pharmacokinetics (PK) is the maximum observed drug concentration (Cmax) of LY3202626</description>
          <population>All randomized participants who received at least one dose and who had evaluable PK data.</population>
          <units>nanogram/milliliter (ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.9" spread="64"/>
                    <measurement group_id="O2" value="36.1" spread="45"/>
                    <measurement group_id="O3" value="39.4" spread="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of LY3202626</title>
        <description>PK is the area under the concentration versus time curve from time zero to infinity (AUC[0-∞]) of LY3202626</description>
        <time_frame>Predose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, 168 Hours Postdose</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>12 mg LY3202626 (R-Fasting)</title>
            <description>Single oral 12 mg dose of LY3202626 capsule (R) under fasting conditions.</description>
          </group>
          <group group_id="O2">
            <title>12 mg LY3202626 (T1-Fasting)</title>
            <description>Single oral 12 mg dose of LY3202626 tablet (T1) under fasting conditions.</description>
          </group>
          <group group_id="O3">
            <title>12 mg LY3202626 (T1-Fed)</title>
            <description>Single oral 12 mg dose of LY3202626 tablet (T1) following a high fat breakfast.</description>
          </group>
        </group_list>
        <measure>
          <title>PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of LY3202626</title>
          <description>PK is the area under the concentration versus time curve from time zero to infinity (AUC[0-∞]) of LY3202626</description>
          <population>All randomized participants who received at least one dose of study drug and had evaluable PK data.</population>
          <units>hour*nanogram/milliliter (h*ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="540" spread="62"/>
                    <measurement group_id="O2" value="707" spread="45"/>
                    <measurement group_id="O3" value="702" spread="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK: AUC From Time Zero to Time t, Where t is the Last Time Point With a Measurable Concentration (AUC[0-tlast]) of LY3202626</title>
        <description>PK is the AUC from time zero to time t, where t is the last time point with a measurable concentration (AUC[0-tlast]) of LY3202626</description>
        <time_frame>Predose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, 168 Hours Postdose</time_frame>
        <population>All randomized participants who received at least one dose of study drug and who had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>12 mg LY3202626 (R-Fasting)</title>
            <description>Single oral 12 mg dose of LY3202626 capsule (R) under fasting conditions.</description>
          </group>
          <group group_id="O2">
            <title>12 mg LY3202626 (T1-Fasting)</title>
            <description>Single oral 12 mg dose of LY3202626 tablet (T1) under fasting conditions.</description>
          </group>
          <group group_id="O3">
            <title>12 mg LY3202626 (T1-Fed)</title>
            <description>Single oral 12 mg dose of LY3202626 tablet (T1) following a high fat breakfast.</description>
          </group>
        </group_list>
        <measure>
          <title>PK: AUC From Time Zero to Time t, Where t is the Last Time Point With a Measurable Concentration (AUC[0-tlast]) of LY3202626</title>
          <description>PK is the AUC from time zero to time t, where t is the last time point with a measurable concentration (AUC[0-tlast]) of LY3202626</description>
          <population>All randomized participants who received at least one dose of study drug and who had evaluable PK data.</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="531" spread="62"/>
                    <measurement group_id="O2" value="667" spread="47"/>
                    <measurement group_id="O3" value="691" spread="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline to End of Study (Up to 3 Months)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>12 mg LY3202626 (R-Fasting)</title>
          <description>Single oral 12 mg dose of LY3202626 capsule (R) under fasting conditions.</description>
        </group>
        <group group_id="E2">
          <title>12 mg LY3202626 (T1-Fasting)</title>
          <description>Single oral 12 mg dose of LY3202626 tablet (T1) under fasting conditions.</description>
        </group>
        <group group_id="E3">
          <title>12 mg LY3202626 (T1-Fed)</title>
          <description>Single oral 12 mg dose of LY3202626 tablet (T1) following a high fat breakfast.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 19.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter site bruise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Catheter site erythema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Catheter site pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Catheter site swelling</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Vessel puncture site bruise</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
      <email>ClinicalTrials.gov@lilly.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

